Moderna Price Target Raised To $139 From $107 At Goldman Sachs

Goldman Sachs analyst Salveen Richter raised the firm's price target on Moderna to $139 from $107 and keeps a Buy rating on the shares.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.